IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IPO Year: 2019
Exchange: NASDAQ
Website: igmbio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/9/2024 | $9.00 → $21.00 | Sector Perform → Outperform | RBC Capital Mkts |
12/15/2023 | $8.00 | Buy → Neutral | BofA Securities |
12/7/2023 | $11.00 → $7.00 | Buy → Neutral | H.C. Wainwright |
11/9/2022 | $61.00 → $55.00 | Buy | Jefferies |
10/17/2022 | $27.00 | Neutral | JP Morgan |
8/29/2022 | $34.00 | Buy | BofA Securities |
12/16/2021 | $114.00 → $76.00 | Buy | HC Wainwright & Co. |
12/14/2021 | $100.00 → $38.00 | Overweight → Equal-Weight | Morgan Stanley |
12/13/2021 | $98.00 → $65.00 | Buy | Stifel |
12/13/2021 | $101.00 → $126.00 | Buy | Jefferies |
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13D/A - IGM Biosciences, Inc. (0001496323) (Subject)
RBC Capital Mkts upgraded IGM Biosciences from Sector Perform to Outperform and set a new price target of $21.00 from $9.00 previously
BofA Securities downgraded IGM Biosciences from Buy to Neutral and set a new price target of $8.00
H.C. Wainwright downgraded IGM Biosciences from Buy to Neutral and set a new price target of $7.00 from $11.00 previously
Jefferies resumed coverage of IGM Biosciences with a rating of Buy and set a new price target of $55.00 from $61.00 previously
JP Morgan initiated coverage of IGM Biosciences with a rating of Neutral and set a new price target of $27.00
BofA Securities initiated coverage of IGM Biosciences with a rating of Buy and set a new price target of $34.00
HC Wainwright & Co. reiterated coverage of IGM Biosciences with a rating of Buy and set a new price target of $76.00 from $114.00 previously
Morgan Stanley downgraded IGM Biosciences from Overweight to Equal-Weight and set a new price target of $38.00 from $100.00 previously
Stifel reiterated coverage of IGM Biosciences with a rating of Buy and set a new price target of $65.00 from $98.00 previously
Jefferies reiterated coverage of IGM Biosciences with a rating of Buy and set a new price target of $126.00 from $101.00 previously
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
8-K - IGM Biosciences, Inc. (0001496323) (Filer)
10-Q - IGM Biosciences, Inc. (0001496323) (Filer)
SC TO-I/A - IGM Biosciences, Inc. (0001496323) (Subject)
8-K - IGM Biosciences, Inc. (0001496323) (Filer)
SC TO-I/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC TO-I/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC TO-I - IGM Biosciences, Inc. (0001496323) (Subject)
SC TO-C - IGM Biosciences, Inc. (0001496323) (Subject)
8-K - IGM Biosciences, Inc. (0001496323) (Filer)
8-K - IGM Biosciences, Inc. (0001496323) (Filer)
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. Ab
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. "We are pleased to have exceeded our enrollment target of 110 patients in our randomized study of 3 mg/kg of aplitabart plus FOLFIRI and bevacizumab in second line colorectal cancer," said Fred Schwa
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About IGM Biosciences, Inc.IGM Bio
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company's exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets. IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collaboration. "We are very pleased with our collaboration with Sanofi and with the preclinical data that we have generated in both the immunology/inflammation and the oncology portions of th
MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 12:00 p.m. EDT. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments. "We made significant progress during 2023 in the clinical development of our two lead product candidates in therapeutic areas that we believe have the greatest potential to produce significant near-term value," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "Enrollment in our randomized clinical trial of aplitabart plus FOLFIRI and bevacizumab in
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 90
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, today December 6, 2023. CEO Jens Lindberg will present at 14.30 CET, with focus on the latest developments and the company's future plans. This will include, among other things, the company's rights issue and how it aims to ensure the highest possible speed and momentum in the development program for fostrox with the aim of starting a pivotal phase 2b study in 2024. The presentation is live broadcasted and can be
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. "We are pleased to have exceeded our enrollment target of 110 patients in our randomized study of 3 mg/kg of aplitabart plus FOLFIRI and bevacizumab in second line colorectal cancer," said Fred Schwa
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments. "We made significant progress during 2023 in the clinical development of our two lead product candidates in therapeutic areas that we believe have the greatest potential to produce significant near-term value," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "Enrollment in our randomized clinical trial of aplitabart plus FOLFIRI and bevacizumab in
– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023. "During the third quarter, we continued to execute across our clinical development pipeline," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "We have significantly expanded the number of active sites for our aplitabart randomized study, including multiple international s
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients – – Progression-free survival of 5.6 months in median third-line colorectal cancer patients without bevacizumab – – Promising safety profile in combination with FOLFIRI and bevacizumab – – Randomized combination trial in second-line colorectal cancer patients initiated in Q1 2023 – MOUNTAIN VIEW, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced an update on its clinical development program for IGM-
– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that it will host a conference call and live webcast to provide an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, on Friday, June 2, 2023 at 7:00 p.m. ET. The Company will be providing a clinical data update on 3 mg/kg IGM-8444 + FOLFIRI (± bevacizumab) in median third line metastatic colorectal cancer patients from a non-randomized clinical trial cohort. The event will feature
HUDDINGE, Sweden, May 16, 2023 /PRNewswire/ -- In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) ("Medivir") on 4 May 2023 ("LTIP 2023"), it is today announced that the board of directors of Medivir has resolved on (i) a share issue of 970,500 shares of series C, (ii) repurchase of the 970,500 shares of series C, (iii) reclassification of 105,750 shares of series C into ordinary shares and (iv) partial execution of the annual general meeting's resolution on transfer of own ordinary shares by transferring 105,750 own ordinary shares to participants in LTIP 2023. Aktieinvest FK AB will subscribe for all 970,500 shares of series C at a subscription pri
– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle of 2023 – – Plans to begin clinical testing of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis – MOUNTAIN VIEW, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on
– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial – – Imvotamab to move forward into clinical studies in multiple autoimmune diseases – – Initiation of Phase 1 clinical trial for targeted immunostimulatory IL-15 cytokine IGM-7354 in patients with solid tumors – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 20
MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 30, 2023. In connection with the earnings release, IGM's management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, March 30, 2023, to discuss the Company's financial results and provide a corporate update. The webcast can be accessed by clicking the link: https://edge.media-server.com/mmc/p/ud83kix8 and will be available on the "Events and Presentations" p
STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology. He joins from Sedana Medical where he has been VP Commercial and acting CEO. Jens Lindberg started his career in the pharmaceutical industry in 1995 as a sales representative for Astra, later AstraZeneca. During a 25-year span at AstraZeneca, Jens held numerous roles in Commercial & Investor Relations, spanning local & global responsibilities as well as development of phase 2/3 programs to maximise the commercial value for o
– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler, M.D., Appointed as President of IGM Autoimmunity and Inflammation – MOUNTAIN VIEW, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation. These new business units will utilize and build upon IGM's platform technology to create and develop novel IgM and IgA antibodies to ad
STOCKHOLM, July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest October 1, 2021. Malene Jensen will also join the company's executive team. Malene Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including at AstraZeneca, Affibody and most recently as Director Global Clinical Development at Sedana Medical. She holds a PhD in Clinical Neuroscience from Karolinska Institutet in Stockholm. "We are pleased to welcome Malene and her vast cl
STOCKHOLM, April 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen, the company's CFO, as interim CEO of Medivir. Magnus has been CFO of the company since 2019 and will take up his new role in connection with Medivir's Annual General Meeting on May 5, 2021. Magnus will in parallel retain his role as CFO. As previously communicated, Yilmaz Mahshid will leave his position as CEO at the Annual General Meeting (AGM) 2021. Medivir's nomination committe proposes that Yilmaz Mahshid is elected new board member at the AGM. The Board has initiated the recruitment process for a new CEO. - Magnus Christensen has been a
MOUNTAIN VIEW, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of George A. Gauthier to the newly created position of Chief Commercial Officer. Mr. Gauthier joins IGM with twenty years of experience in global commercial strategy, marketing, sales and product development. Most recently, Mr. Gauthier was Vice President of Global Product Strategy for Breast and Gynecological Cancers at Genentech, where he led a global team in the creation and execution of commercial and product development strategies. "We are delighted to have Ge
The Russell 2000 index of small caps, tracked by the iShares Russell 2000 ETF (NYSE:IWM), recorded its best weekly performance since October 2023, surging over 6% and reaching its highest level since January 2022. The rally was largely driven by Thursday’s session, where the Russell 2000 posted a remarkable 3.6% daily gain. This spike followed lower-than-expected June inflation data, which fueled speculation of potential interest rate cuts. However, Quincy Krosby, chief global strategist for LPL Financial, advises caution, suggesting that Russell 2000’s rate cut message may be “clouded by Fed’s concerns over labor market.” Krosby thinks a weaker labor market would still hurt the eco
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro. Conagra Brands shares declined 3.9% to $27.70 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced result
IGM Biosciences (NASDAQ:IGMS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 1 0 0 3M Ago 0 2 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for IGM Biosciences, presenting an average target of $16.17, a high estimate of $21.00, and a low estimate of $12.00. Marking an incr
HC Wainwright & Co. analyst Robert Burns reiterates IGM Biosciences (NASDAQ:IGMS) with a Neutral and maintains $12 price target.
Shares of XP Inc. (NASDAQ:XP) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results. XP posted quarterly earnings of 37 cents per share, missing market estimates of 40 cents per share. The company's quarterly sales came in at $818.79 million versus expectations of $784.08 million, according to data from Benzinga Pro. XP shares dipped 11.5% to $18.99 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Akoustis Technologies, Inc. (NASDAQ:AKTS) shares climbed 213.3% to $0.4254 after the company reportedly floated the probability of bankruptcy after losing a lawsuit against Qorvo. Barnes
Gainers IGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 21.96% to $1.05. The company's market cap stands at $153.8 million. MultiPlan (NYSE:MPLN) shares rose 18.57% to $0.64. The company's market cap stands at $415.4 million. Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 14.61% to $2.98. The company's market cap stands at $7.4 million. TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 12.79% to $1.41. The company's market cap stands at $9.3 million. Indaptus Therapeutics (NASDAQ:INDP) shares moved upward
U.S. stocks were slightly lower, with the Dow Jones index falling around 10 points on Wednesday. Shares of Analog Devices, Inc. (NASDAQ:ADI) rose sharply during Wednesday's session following better-than-expected second-quarter financial results. Analog Devices posted adjusted earnings of $1.40 per share, beating market estimates of $1.26 per share. The company's quarterly sales came in at $2.160 billion versus expectations of $2.106 billion, according to data from Benzinga Pro. Analog Devices shares surged 6% to $229.69 on Wednesday. Here are some other big stocks recording gains in today's session. IGM Biosciences, Inc. (NASDAQ:IGMS) jumped 24% to $10.44. Petco Health and
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share. Virios Therapeutics shares dipped 47.6% to $0.1850 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers MultiMetaVerse Holdings Limited (NASDAQ:MMV) shares jumped 224% to $2.01. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries. GT Biopharma, Inc. (NASDAQ:GTBP) rose 146% to $7.64. GT Biopharma, last week, posted a narrower-than-expected quarterly loss. Tantech Hold
Wedbush analyst Robert Driscoll reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $20 price target.
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 37.59 percent increase over losses of $(1.33) per share from the same period last year. The company reported quarterly sales of $497.00 thousand which missed the analyst consensus estimate of $760.00 thousand by 34.61 percent. This is a 4.79 percent decrease over sales of $522.00 thousand the same period last year.